NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Cardiovascular Devices M&A update, 14–28 September 2026

A bi-weekly update on cardiovascular devices covering public market moves, major company news and M&A activity for September 14–28, 2026, built for investors, operators and advisors tracking performance and deal activity across the sector.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Cardiovascular Devices Sector Outlook — September 2026

Key figures

Kestra Medical Technologies (KMTS) share move
+16.9%
close-to-close, Sept 14–28, 2026
Sector median move
-0.1%
14 covered names
S&P 500 return
+0.8%
same two-week period
Integer Holdings (ITGR) proposed buyout price
$127.00
per share

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CARDIOVASCULAR DEVICES

Delivered Results Separate the Premium Names from the Pack

This update covers what moved, what companies announced and what changed in the transaction record across cardiovascular devices from September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Cardiovascular Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Across the 14 covered cardiovascular devices names, the median share move was -0.1% against a +0.8% S&P 500 return over September 14–28, 2026. Kestra Medical Technologies, Ltd. (KMTS) led the period, up +16.9% after reporting $31 million in first quarter fiscal 2027 revenue, up 60% year over year. Two law firms opened reviews of the proposed $127.00 per share buyout of Integer Holdings Corporation (ITGR), and Orchestra BioMed Holdings, Inc. (OBIO) received a $6.1 million milestone payment. Delivery, not category position, set the spread across the sector this period.

Key findings

  • Growth reaching the top line was rewarded; the rest of the set drifted lower.
  • Kestra Medical Technologies, Ltd. (KMTS) led the period, up +16.9% on reported growth.
  • A proposed $127.00 per share buyout of Integer Holdings (ITGR) faces legal review.
  • Orchestra BioMed (OBIO) banked a $6.1 million milestone payment mid-period.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CARDIOVASCULAR DEVICES

    Cover page introducing the cardiovascular devices bi-weekly industry events and M&A update for September 14–28, 2026.

    This bi-weekly update tracks what changed, who moved and why, what transacted, and what it means across cardiovascular devices for September 14–28, 2026. We'll walk through the market moves, the news, and the deal activity that mattered most this period.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CARDIOVASCULAR DEVICES Delivered Results Separate the Premium Names from the Pack This update covers what moved, what companies announced and what changed in the transaction record across cardiovascular devices from September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Cardiovascular Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Growth That Showed up in the Numbers Got Paid; The Rest of the Set Drifted

    Summarizes the two-week period's market performance and key events across the 14 covered cardiovascular devices names.

    We open with the headline: eight of fourteen covered names fell, with a median move of -0.1% against a +0.8% S&P 500 return. Kestra Medical Technologies, Ltd. (KMTS) was the standout, up +16.9% after reporting $31 million in revenue, up 60% year over year. Two law firms are now reviewing the proposed $127.00 per share buyout of Integer Holdings Corporation (ITGR), and Orchestra BioMed Holdings, Inc. (OBIO) collected a $6.1 million milestone payment. So growth that showed up in the numbers got paid, while the rest of the set drifted.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Growth That Showed up in the Numbers Got Paid; The Rest of the Set Drifted The two-week period in one page · 14 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Cardiovascular Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 The Covered Set Leaned Lower While the Broad Market Rose 8 of 14 covered names fell; the median move was -0.1%. The S&P 500 returned +0.8% over the same two-week period. 2 One Quarter Carried the Period's Upside Kestra Medical Technologies, Ltd. (KMTS) gained +16.9%. The company reported first quarter fiscal 2027 revenue of $31 million on September 14, up 60% from a year earlier, with a loss of $0.75 per share against a $0.61 consensus loss. 3 A Proposed Take-Out of a Scaled Supplier Is Being Argued in Public Two law firms opened reviews inside the window of the proposed $127.00 per share buyout of Integer Holdings Corporation (ITGR), one on September 22 and one on September 24. 4 Structured Consideration Paid Out Rather than Lapsed Orchestra BioMed Holdings, Inc. (OBIO) received a $6.1 million milestone payment on September 15, bringing total cash proceeds to roughly $11 million with up to about $10 million more possible through revenue earnouts. +16.9% Best mover — KMTS worst: AVR -11.2% · 6 up / 8 down of 14 covered -0.1% Sector median two-week return vs S&P 500 +0.8% 1 Transaction agreed in the two-week period from company announcements; not yet in the precedent record 1 Company filings in the window 8-K events read for driver attribution

  3. 03
    PUBLIC MARKET MOVERS

    Where the Period Paid: One Quarter Led, and the Premium Tier Split Both Ways

    Shows which covered names moved most over the period and how the premium tier split between gainers and decliners.

    One name carried the period's upside: Kestra Medical Technologies, Ltd. (KMTS) rose +16.9% on the back of reported growth. The premium tier itself split, with the same tier showing a -11.2% move alongside that gain. Against a sector median of -0.1% and a +0.8% S&P 500 return, moves against our 4.1% materiality bar are the ones worth explaining. So the period's real story is dispersion within the same tier, not a uniform trade.

    Everything on this page

    PUBLIC MARKET MOVERS Where the Period Paid: One Quarter Led, and the Premium Tier Split Both Ways Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -0.1% · S&P 500 +0.8% · materiality bar ±4.1% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Cardiovascular Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -0.1% Kestra Medical Technologies, Ltd. (KMTS) +16.9% Shares moved following the September 14 first quarter fiscal 2027 results: revenue of $31 million, up 60% from a year earlier, and a loss of $0.75 per share against a $0.61 consensus loss. A Premium-tier name still has to show procedure growth arriving in the top line to hold its position. COMPANY-SPECIFIC AtriCure, Inc. (ATRC) +4.7% No notable in-window news was identified that clearly explains the move. At +4.7%, AtriCure, Inc. (ATRC) ran ahead of the set's -0.1% median. Core-tier names carried most of the upside outside the period's single large earnings move. UNEXPLAINED Medtronic plc (MDT) -4.6% Shares moved following the September 14 launch of an exchange offer to complete a previously announced business separation; the company also announced FDA clearance for a vessel-sealing instrument on its robotic system on September 16. Portfolio separations at the large-cap end reshape the comparison set everyone else is measured against. COMPANY-SPECIFIC LivaNova PLC (LIVN) -4.2% No notable in-window news was identified that clearly explains the move. At -4.2%, LivaNova PLC (LIVN) finished below the set's -0.1% median. In quiet windows the reference set is the only honest yardstick for a move. UNEXPLAINED

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    What Companies Did: A Clearance, a Separation, a Milestone and a Contested Price

    Details the period's highest-impact company events, including a milestone payment and a contested buyout price.

    This page walks through the two-week period's highest-impact events, from routine execution to a live pricing dispute. Orchestra BioMed Holdings, Inc. (OBIO) banked a $6.1 million milestone payment, while the proposed $127.00 per share buyout of Integer Holdings Corporation (ITGR) drew two separate law firm reviews. Each event links back to the filing or article that recorded it, so nothing here is speculative. So the period's catalysts ranged from delivering on structured payouts to arguing over a live acquisition price.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS What Companies Did: A Clearance, a Separation, a Milestone and a Contested Price The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Cardiovascular Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 23 · NEWS · PRNewsWire LeMaitre Vascular faces a class action review after a reported customer data breach Compliance and data-handling questions sit in the same diligence file as quality system findings for this sector. The NeuraCap read: a Core-tier name now has an open item a counterparty would test. The compliance file travels with the clinical file in device diligence. Sep 22 · NEWS · Business Wire Law firm opened a review of the $127.00 per share buyout offer for Integer Holdings A proposed take-out of a scaled component and contract manufacturing business gives the sector a live price reference for cash-generative assets with settled customer demand. Pricing for outsourced manufacturing capability is being tested where everyone can see it. Sep 16 · NEWS · PRNewsWire Medtronic won FDA clearance for a vessel-sealing instrument on its robotic surgery system Clearance-level iteration on an installed platform is how an incumbent widens disposable pull-through without taking fresh pivotal trial risk. Approved platforms compound through supplements and clearances faster than a new entrant can arrive. Sep 16 · NEWS · GlobeNewsWire A former Medtronic chief regulatory counsel took a medtech board seat Approval-pathway and regulatory experience is being recruited at board level, which the NeuraCap read takes as a marker of where boards think the value and the risk sit. Board composition is one visible signal of a company's view of its own regulatory exposure. Sep 16 · NEWS · GlobeNewsWire Orchestra BioMed put its AVIM therapy in front of clinicians in two sessions at a heart-rhythm meeting Podium time is how a partnership-led developer builds the evidence profile that precedes coverage decisions and implanting centre activation. Evidence circulation runs ahead of procedure adoption in any new category. Sep 15 · NEWS · GlobeNewsWire Orchestra BioMed collected a $6.1 million milestone payment from an earlier asset monetisation Contingent payments are the sector's normal structure, and this one converted to cash, taking total proceeds to roughly $11 million with up to about $10 million more possible through revenue earnouts. Structured consideration is real money when the underlying franchise clears its defined steps.

  5. 05
    M&A & STRATEGIC ACTIVITY

    Orchestra BioMed Banks a Milestone as Structured Consideration Pays Out

    Highlights the period's M&A activity, led by Orchestra BioMed's milestone payment and the broader precedent transaction set.

    Orchestra BioMed Holdings, Inc. (OBIO) received a $6.1 million milestone payment on September 15, taking total cash proceeds to roughly $11 million with up to about $10 million more possible through revenue earnouts. This is the period's one company-announced agreement, set against a precedent set of 40 recorded deals we track for context. Structured consideration paid out rather than lapsed, which is the signal worth carrying forward. So milestone-based deal structures in this space are showing they can deliver cash on schedule.

    Everything on this page

    M&A & STRATEGIC ACTIVITY Orchestra BioMed Banks a Milestone as Structured Consideration Pays Out September 14–28, 2026 · 1 agreed by company announcement · precedent transactions: 40 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Cardiovascular Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 AGREED IN THE PERIOD — FROM COMPANY ANNOUNCEMENTS Sep 15 · Orchestra BioMed Holdings, Inc. (OBIO) Orchestra BioMed received a $6.1 million milestone payment tied to the completed acquisition of an asset it held an Total cash proceeds now stand at roughly $11 million, with up to about $10 million more possible through revenue earnouts. Terms and multiples enter the precedent record once the filing is processed; the reference set alongside is unchanged. 40 Recorded precedent transactions the reference set buyers and sellers price against

  6. 06
    WHAT IT MEANS

    Three Reads from a Period That Rewarded Delivery

    Translates the period's evidence into three reads for owners and operators, acquirers, and advisors.

    For owners and operators, the period paid for procedure growth reaching the top line: Kestra Medical Technologies, Ltd. (KMTS) rose +16.9% after reporting 60% revenue growth. For acquirers, the proposed $127.00 per share buyout of Integer Holdings Corporation (ITGR) is now a live reference point, being argued over in public via two law firm reviews. For advisors, the dispersion inside the same premium tier, including that +16.9% move set against a -11.2% move, shows why the evidence file matters more than category position. So the same three reads point to one conclusion: delivery, not position, set the spread this period.

    Everything on this page

    WHAT IT MEANS Three Reads from a Period That Rewarded Delivery The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Cardiovascular Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 3.4x 17 companies in the study 3 valuation tiers Standing thesis: Cardiovascular Devices Split Across Diversified Cardiac Franchises, Cath-Lab Products and Vascular Conduits FOR OWNERS & OPERATORS The Period Paid for Procedure Growth Reaching the Top Line Companies in the space that showed growth arriving in reported revenue traded higher: Kestra Medical Technologies, Ltd. (KMTS) rose +16.9% after reporting revenue of $31 million, up 60%. FOR ACQUIRERS A Live Price for Scale Is Now in Open Discussion The proposed $127.00 per share buyout of Integer Holdings Corporation (ITGR) drew two separate law firm reviews inside the window, so the reference point for cash-generative manufacturing assets is being argued over as it is set. FOR ADVISORS Lead with the Evidence File and How the Money Is Structured The period's dominant theme was dispersion inside the same tier: Kestra Medical Technologies, Ltd. (KMTS) at +16.9% and Anteris Technologies Global Corp. (AVR) at -11.2% both sit in the Premium tier.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    Explains the sources and methodology behind the update's figures and calibrated language.

    Every figure in this update links back to the SEC filing, press release or established outlet it came from, and our driver attributions use calibrated language rather than asserted causation. This page sets out exactly how we built the two-week view, so any number can be traced back to its source. So this update can serve as a starting point for further diligence, not a final word.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Cardiovascular Devices Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 3 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T163140Z_521_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: prnewswire.com · businesswire.com · globenewswire.com

Sources and methodology

This update covers Cardiovascular Devices over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 14 listed companies whose core business is Cardiovascular Devices under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: AngioDynamics, Inc. (ANGO), Artivion, Inc. (AORT), AtriCure, Inc. (ATRC), Anteris Technologies Global Corp. (AVR), Edwards Lifesciences Corporation (EW), Integer Holdings Corporation (ITGR), Kestra Medical Technologies, Ltd. (KMTS), LivaNova PLC (LIVN), LeMaitre Vascular, Inc. (LMAT), Medtronic plc (MDT), Merit Medical Systems, Inc. (MMSI), Orchestra BioMed Holdings, Inc. (OBIO), Penumbra, Inc. (PEN), Pulse Biosciences, Inc. (PLSE). 3 names below the floor were excluded from the statistics: CVRX, HUMA, NSPR.

Window and company universe

This update covers Cardiovascular Devices over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 14 listed companies whose core business is Cardiovascular Devices under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: AngioDynamics, Inc. (ANGO), Artivion, Inc. (AORT), AtriCure, Inc. (ATRC), Anteris Technologies Global Corp. (AVR), Edwards Lifesciences Corporation (EW), Integer Holdings Corporation (ITGR), Kestra Medical Technologies, Ltd. (KMTS), LivaNova PLC (LIVN), LeMaitre Vascular, Inc. (LMAT), Medtronic plc (MDT), Merit Medical Systems, Inc. (MMSI), Orchestra BioMed Holdings, Inc. (OBIO), Penumbra, Inc. (PEN), Pulse Biosciences, Inc. (PLSE). 3 names below the floor were excluded from the statistics: CVRX, HUMA, NSPR.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Cardiovascular Devices?

Company valuation reports run the same method against a single business — public or private.